A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations Meeting Abstract

  

Authors:	Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; Tallman, M. S.
Abstract Title:	A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
Meeting Title:	65th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	142
Issue:	Suppl. 1
Meeting Dates:	2023 Dec 9-12
Meeting Location:	San Deigo, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2023-11-02
Start Page:	5945
Language:	English
ACCESSION:	WOS:001159900803231
DOI:	10.1182/blood-2023-190801
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/215347